Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.49 |
| ▸ | MC4R | P32245 | 9/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990184 | 0.92 | MC4R (0.43) | SLC2A1MC4RMC5RMC3R | |
| SCHEMBL8039020 | 0.88 | SLC2A1 (0.46) | SLC2A1MC4RMEN1KMT2AMC5R | |
| SCHEMBL12990177 | 0.87 | MC4R (0.38) | SLC2A1MC4RKDM5BMC5RMC3R | |
| SCHEMBL8022977 | 0.81 | MC4R (0.41) | SLC2A1MC4RMC5RMC3R | |
| SCHEMBL14046560 | 0.75 | SLC2A1 (0.50) | SLC2A1MEN1KMT2ASLC2A2 | |
| SCHEMBL11929574 | 0.75 | MC4R (0.47) | SLC2A1MC4RMC5RMC3R | |
| SCHEMBL4671552 | 0.74 | SLC2A1 (0.49) | SLC2A1MEN1KMT2ASLC2A2 | |
| SCHEMBL11929564 | 0.74 | MC4R (0.50) | SLC2A1MC4RMC5RMC3R | |
| SCHEMBL11929586 | 0.73 | MC4R (0.52) | SLC2A1MC4RMC5RMC3R | |
| SCHEMBL4669868 | 0.72 | MC4R (0.45) | SLC2A1MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324036-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | MC4R, MC5R, MC3R | SLC2A1 4133/4885MC4R 1/4885KDM5B 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.